ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Monday, November 13, 2023

9:00AM-11:00AM: Abstract Number: 0897

Steroid-sparing Effects of Afimetoran (BMS-986256), an Equipotent Toll-like Receptor (TLR)7 and TLR8 Antagonist, in a Lupus Mouse Model

(0886–0898) SLE – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 1231

Successful Implementation of a Mental Health Screening Program for Youth with Juvenile Dermatomyositis

(1221–1255) Pediatric Rheumatology – Clinical Poster II: Connective Tissue Disease

9:00AM-11:00AM: Abstract Number: 0993

Successful Implementation of a New Patient Video Triage Program

(0993–1012) Health Services Research Poster II

9:00AM-11:00AM: Abstract Number: 1397

Sustainability of Clinical Response at Week 52 to Upadacitinib Among Patients with Axial SpA: Data from the SELECT-AXIS 1 and SELECT-AXIS 2 Trials

(1383–1411) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster II: Imaging & AS

9:00AM-11:00AM: Abstract Number: 1328

Switching Biologics or Janus Kinase Inhibitors Is Effective in Difficult-to-treat Rheumatoid Arthritis, Regardless of Inflammation

(1308–1344) RA – Treatments Poster II

9:00AM-11:00AM: Abstract Number: 1380

Synergistic Dose Effects of Extra X Chromosome in Development of Sjogren’s Syndrome in Klinefelter and Triple X Syndromes

(1365–1382) Sjögren’s Syndrome – Basic & Clinical Science Poster I

9:00AM-11:00AM: Abstract Number: 0872

Synovial 5-LOX-Derived Oxylipins Define a B Cell-Enriched Synovium

(0859–0885) Osteoarthritis & Joint Biology – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 0878

Synovial Fibroblasts Undergo a Phenotypic Shift from Early- to Late-stage Knee Osteoarthritis

(0859–0885) Osteoarthritis & Joint Biology – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 1370

Synthetic Glabridin Derivatives Improves Sjogren’s Syndrome by Inducing Salivary Secretion and Salivary Gland Regeneration

(1365–1382) Sjögren’s Syndrome – Basic & Clinical Science Poster I

9:00AM-11:00AM: Abstract Number: 1456

Systematic Review of Effects of Systemic Lupus Erythematosus on Brain Structure and Structural Connectivity and Its Relationship with Cognitive Dysfunction Through an Advanced Neuroimaging Lens

(1442–1487) SLE – Diagnosis, Manifestations, & Outcomes Poster II

9:00AM-11:00AM: Abstract Number: 0982

Systemic Autoimmune Rheumatic Diseases (SARD) in the Agricultural Health Study Cohort: Rates of Rheumatoid Arthritis (RA) and Other SARD Among Medicare-linked Participants

(0965–0992) Epidemiology & Public Health Poster II

9:00AM-11:00AM: Abstract Number: 1101

Systemic Inflammation Associated with Silent Deposition of Monosodium Urate Crystals in Asymptomatic Hyperuricemia

(1100–1123) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II

9:00AM-11:00AM: Abstract Number: 1280

Systemic Inflammation Is Associated with Incident Valvular Heart Disease in Patients with Rheumatoid Arthritis: A Multicenter, Prospective Cohort Study

(1264–1307) RA – Diagnosis, Manifestations, and Outcomes Poster II

9:00AM-11:00AM: Abstract Number: 1357

Systemic Lupus Erythematosus and Assisted Reproductive Technology: A Case Series and Systematic Literature Review

(1345–1364) Reproductive Issues in Rheumatic Disorders Poster II

9:00AM-11:00AM: Abstract Number: 0964

Systemic Sclerosis (SSc) Dermal Fibroblasts Show Shortened Primary Cilia Due to Aberrant Aurora a Kinase Activation Independently of Transforming Growth Factor β Signalling

(0934–0964) Systemic Sclerosis & Related Disorders – Basic Science Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].